Acute myocardial infarction.
Because of advances in reperfusion therapy and improved outcomes through the use of treatment adjuncts, the morbidity and mortality from AMI have been significantly reduced in the past decade. Reperfusion therapy is now the standard of care for all patients who meet eligibility criteria. Equally important in the treatment of AMI, however, are the many treatment adjuncts that are universally available (Table 1). Aspirin and beta-blockers should be used in all patients without contraindications. Heparin, in turn, has a clear role in many but not all patients. Finally, the best application of magnesium has yet to be determined.
Sirois
J G
JG
Joint Military Medical Centers at San Antonio, Fort Sam Houston, Texas, USA.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000175:diagnosis / Q000628:therapy*; D015425:Myocardial Reperfusion; D005996:Nitroglycerin / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D006493:Heparin; D005996:Nitroglycerin